Stock comparison
Amphastar Pharmaceuticals
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMPH
Amphastar Pharmaceuticals
Market cap
$811.75M
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMPH | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 71B | UTHR |
| Benjamin Graham | 50C | 76B | UTHR |
| Philip Fisher | 50C | 76B | UTHR |
| Peter Lynch | 40D | 62C | UTHR |
| Joel Greenblatt | 22F | 46D | UTHR |
| Charlie Munger | 44D | 64C | UTHR |
| Terry Smith | 50D | 64C | UTHR |
Side-by-side metrics
| Metric | AMPH | UTHR |
|---|---|---|
| Market cap | $811.75M | $24.13B |
| P/E (TTM) | 10.6x | 19.2x |
| EV/EBIT | 5.1x | 15.2x |
| ROIC (TTM) | 6.02% | 18.81% |
| Gross margin | 47.34% | 86.58% |
| Net margin | 11.0% | 40.61% |
| Revenue CAGR 5y | 13.24% | 17.22% |
| EPS CAGR 5y | 12.74% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMPH leads on
- EV/EBIT5.1xvs 15.2x+66%
- P/E (TTM)10.6xvs 19.2x+45%
UTHR leads on
- Debt / Equity-vs 0.1x+100%
- Market cap$24.13Bvs $811.75M+97%
- Net margin40.61%vs 11.0%+73%
- ROIC (TTM)18.81%vs 6.02%+68%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.